Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alector Inc.
Headquarters: South San Francisco, CA, United States of America
Website: http://alector.com
Year Founded: 2013
Status: Public
Industry Sector: HealthTechnology
CEO: Arnon Rosenthal, PhD
Number Of Employees: 238
Enterprise Value: $-188,326,345
PE Ratio: -0.88
Exchange/Ticker 1: NASDAQ:ALEC
Exchange/Ticker 2: N/A
Latest Market Cap: $108,003,600
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New mechanisms in obesity, neurology, ophthalmology
New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Nov 27, 2024
Product Development
Biohaven’s Phase III SMA miss: was it the target or the trial design?
BioCentury’s latest Clinical Report also analyzes results from Alector, NewAmsterdam and Pyxis that led shares to slip, and more
BioCentury | Nov 11, 2024
Product Development
AbbVie’s schizophrenia miss: implications for itself, BMS and M4 pipeline
Price tag of AbbVie’s Cerevel deal now harder to justify, as BMS’s first-mover advantage extends and M4 PAMs come into question
BioCentury | Jun 21, 2024
Product Development
Rare Disease Spotlight: Rare form of dementia a gateway indication for PGRN?
Half a dozen programs aim to boost PGRN expression in the CNS. They are targeting FTD-GRN as a proving ground
BioCentury | Apr 2, 2024
Product Development
Neurology’s false choice: symptomatic vs. disease-modifying
A new theme in Alzheimer’s is aiming for early symptom relief PLUS long-term disease modification
BioCentury | Feb 28, 2024
Emerging Company Profile
Vesper Bio: a sortilin-targeting pill to treat neurological disease
Lundbeckfonden-backed start-up believes at-home oral therapy would offer benefits over injectables for genetically defined patients with dementia
BioCentury | Jan 19, 2024
Finance
Public equity roundup: Edgewise shares get lift after $240M offering
Plus offerings by Immatics, Viridion, Alector, LegoChem and more
BioCentury | Jan 18, 2024
Discovery & Translation
Proteomics study identifies five subtypes of Alzheimer’s
Each one may require different treatments and have different safety considerations
Items per page:
1 - 10 of 65